By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Merck stock snapshot after recent performance Merck (MRK) has drawn fresh attention after a period where the share price and ...

Jan 21 (Reuters) - Merck & Co unit MSD and the Coalition for Epidemic Preparedness Innovations said on Wednesday they have ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

Jan 8 (Reuters) - Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

RAHWAY, N.J. - Merck is officially adding an experimental flu prevention drug to its portfolio. The New Jersey-based pharmaceutical giant has completed its $9.2 billion acquisition of Cidara ...

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...